Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels

DOI Web Site 被引用文献21件
  • Paul M. Ridker
    From the Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children’s Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).
  • Nader Rifai
    From the Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children’s Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).
  • Marc A. Pfeffer
    From the Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children’s Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).
  • Frank M. Sacks
    From the Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children’s Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).
  • Lemuel A. Moye
    From the Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children’s Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).
  • Steven Goldman
    From the Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children’s Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).
  • Greg C. Flaker
    From the Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children’s Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).
  • Eugene Braunwald
    From the Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children’s Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).

書誌事項

公開日
1998-09
DOI
  • 10.1161/01.cir.98.9.839
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:p> <jats:italic>Background</jats:italic> —We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk. </jats:p> <jats:p> <jats:italic>Methods and Results</jats:italic> —A nested case-control design was used to compare C-reactive protein (CRP) and serum amyloid A (SAA) levels in prerandomization blood samples from 391 participants in the Cholesterol and Recurrent Events (CARE) trial who subsequently developed recurrent nonfatal MI or a fatal coronary event (cases) and from an equal number of age- and sex-matched participants who remained free of these events during follow-up (control subjects). Overall, CRP and SAA were higher among cases than control subjects (for CRP <jats:italic>P</jats:italic> =0.05; for SAA <jats:italic>P</jats:italic> =0.006) such that those with levels in the highest quintile had a relative risk (RR) of recurrent events 75% higher than those with levels in the lowest quintile (for CRP RR=1.77, <jats:italic>P</jats:italic> =0.02; for SAA RR=1.74, <jats:italic>P</jats:italic> =0.02). The study group with the highest risk was that with consistent evidence of inflammation (elevation of both CRP and SAA) who were randomly assigned to placebo (RR=2.81, <jats:italic>P</jats:italic> =0.007); this risk estimate was greater than the product of the individual risks associated with inflammation or placebo assignment alone. In stratified analyses, the association between inflammation and risk was significant among those randomized to placebo (RR=2.11, <jats:italic>P</jats:italic> =0.048) but was attenuated and nonsignificant among those randomized to pravastatin (RR=1.29, <jats:italic>P</jats:italic> =0.5). </jats:p> <jats:p> <jats:italic>Conclusions</jats:italic> —Evidence of inflammation after MI is associated with increased risk of recurrent coronary events. Therapy with pravastatin may decrease this risk, an observation consistent with a nonlipid effect of this agent. </jats:p>

収録刊行物

  • Circulation

    Circulation 98 (9), 839-844, 1998-09

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (21)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ